TY - JOUR
T1 - Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
AU - Baarslag, Manuel A.
AU - Heimovaara, Joosje H.
AU - Borgers, Jessica S. W.
AU - van Aerde, Koen J.
AU - Koenen, Hans J. P. M.
AU - Smeets, Ruben L.
AU - Buitelaar, Pauline L. M.
AU - Pluim, Dick
AU - Vos, Shoko
AU - Henriet, Stefanie S. V.
AU - de Groot, Jan Willem B.
AU - van Grotel, Martine
AU - Rosing, Hilde
AU - Beijnen, Jos H.
AU - Huitema, Alwin D. R.
AU - Haanen, John B. A. G.
AU - Amant, Frédéric
AU - Gierenz, Nicole
N1 - Publisher Copyright: © 2023 Massachusetts Medical Society.
PY - 2023/11/9
Y1 - 2023/11/9
N2 - Summary Immune checkpoint blockade has become standard treatment for many types of cancer. Such therapy is indicated most often in patients with advanced or metastatic disease but has been increasingly used as adjuvant therapy in those with early-stage disease. Adverse events include immune-related organ inflammation resembling autoimmune diseases. We describe a case of severe immune-related gastroenterocolitis in a 4-month-old infant who presented with intractable diarrhea and failure to thrive after in utero exposure to pembrolizumab. Known causes of the symptoms were ruled out, and the diagnosis of pembrolizumab-induced immune-related gastroenterocolitis was supported by the results of histopathological assays, immunophenotyping, and analysis of the level of antibodies against programmed cell death protein 1 (PD-1). The infant's condition was successfully treated with prednisolone and infliximab.
AB - Summary Immune checkpoint blockade has become standard treatment for many types of cancer. Such therapy is indicated most often in patients with advanced or metastatic disease but has been increasingly used as adjuvant therapy in those with early-stage disease. Adverse events include immune-related organ inflammation resembling autoimmune diseases. We describe a case of severe immune-related gastroenterocolitis in a 4-month-old infant who presented with intractable diarrhea and failure to thrive after in utero exposure to pembrolizumab. Known causes of the symptoms were ruled out, and the diagnosis of pembrolizumab-induced immune-related gastroenterocolitis was supported by the results of histopathological assays, immunophenotyping, and analysis of the level of antibodies against programmed cell death protein 1 (PD-1). The infant's condition was successfully treated with prednisolone and infliximab.
KW - Allergy/Immunology
KW - Autoimmune Disease
KW - Complications of Pregnancy
KW - Gastroenterology
KW - Hematology/Oncology
KW - Inflammatory Bowel Disease
KW - Neonatology
KW - Obstetrics/Gynecology
KW - Obstetrics/Gynecology General
KW - Pediatrics
KW - Treatments in Oncology
UR - http://www.scopus.com/inward/record.url?scp=85176332842&partnerID=8YFLogxK
U2 - https://doi.org/10.1056/NEJMoa2308135
DO - https://doi.org/10.1056/NEJMoa2308135
M3 - Article
C2 - 37937778
SN - 0028-4793
VL - 389
SP - 1790
EP - 1796
JO - New England journal of medicine
JF - New England journal of medicine
IS - 19
ER -